StockData

QuidelOrtho vs Bio-Techne

QDEL and TECH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How QDEL and TECH compare

Bio-Techne is the larger company, worth 14 times as much as QuidelOrtho ($11.4B against $817M).

Bio-Techne grew revenue faster over the last twelve months (0.94% versus −4.5% for QuidelOrtho).

Bio-Techne pays a dividend yielding 0.44%; QuidelOrtho does not pay one.

Bio-Techne scores higher on the StockData Score (11 against 6 for QuidelOrtho), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricQDELTECH
Size and price
Market cap$817M$11.4B
Share price$11.91$72.80
Change, 1 year−39.6%26.7%
Change, 5 years−92.2%−41.9%
Beta (5Y)0.911.07
Employees6,5003,000
StockData Score
Total score611 (better)
Valuation score3 (better)1
Growth score01 (better)
Performance score2 (better)0
Health score16 (better)
Dividend score03 (better)
Valuation
P/E–66.8×
P/S0.3× (better)9.3×
P/B0.5× (better)5.3×
EV/EBITDA10.7× (better)33.4×
P/FCF–37.1×
FCF yield−14.3%2.7% (better)
Fair value$27.66$52.06
Margin of safety56.9% (better)−39.8%
Growth
Revenue growth (TTM)−4.5%0.94% (better)
Revenue growth, 5Y average10.4% (better)5.5%
EPS growth (TTM)–122%
EPS growth, 5Y average–5.9%
Profitability
Gross margin44.2%65.8% (better)
Operating margin−4.9%19.6% (better)
Net margin−14.2%–
FCF margin−4.5%25.1% (better)
Return on equity−19.3%–
Return on invested capital−2.2%8.8% (better)
Financial health
Debt / equity1.640.09 (better)
Net debt / EBITDA8.29 (better)−0.44
Interest coverage−0.6×27.2× (better)
Current ratio1.362.28 (better)
Altman Z-score0.2816.15 (better)
Piotroski F-score6–
Dividends and buybacks
Dividend yield–0.44%
Years of dividend growth–0
Dividend growth, 5Y average–0.00%
Buyback yield−0.55%–
Shareholder yield−0.55%0.44% (better)
Ownership
Held by institutions121%112%
Held by insiders43.4%0.36%
Insider net buying, 12 months$669K (better)−$437K
Superinvestors holding–4
Short interest, % of float37.3%4.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.